FDA Approval to Commence Huntington’s Disease Clinical Trial Using Prana’s PBT2: Huntington Study Group appointed to coordinate the trial and start recruitment July 17, 2013
Prana Announces that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation July 17, 2013
